Search Structure Search
wx_img
Inquiry Form
  1. Home
  2. NT-0796

NT-0796

NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s Disease phase Ib/IIa trial. The positive data from its Phase Ib/IIa study indicates that NT-0796 reduces key neuroinflammatory and inflammatory biomarkers in Parkinson’s disease patients to the levels found in healthy elderly controls over 28 days.
The NLRP3 inflammasome is a main mediator of inflammation in many pathologies. NT-0796 selectively inhibits NLRP3, lowering levels of both pro-inflammatory cytokines IL-1β and IL-18. This action delivers therapeutic effects directly to immune cell types responsible for inflammatory diseases, including peripheral and neuroinflammatory diseases.

Indan
Indan
CM303297
496-11-7
3-Chloro-1-(2,3-dihydro-1H-inden-5-yl)propan-1-one
3-Chloro-1-(2,3-dihydro-1H-inden-5-yl)propan-1-one
CM269839
39105-39-0
1,2,3,5,6,7-Hexahydro-s-indacen-4-amine
1,2,3,5,6,7-Hexahydro-s-indacen-4-amine
CM219878
63089-56-5
4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene
4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene
CM630069
210827-31-9
2-Methylpyrimidine
2-Methylpyrimidine
CM121142
5053-43-0
Ethyl 2,2,2-triethoxyacetate
Ethyl 2,2,2-triethoxyacetate
CM253734
57267-03-5